Relationship between glutamate dysfunction and symptoms and cognitive function in psychosis

Frontiers in Psychiatry

Volumn 4, Issue NOV, 2013, Pages

  Merritt, Kate ^a   McGuire, Philip ^a   Egerton, Alice ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Glutamate; Imaging; MRS; NMDA; Psychosis; schizophrenia; Spectroscopy

Indexed keywords

CLOZAPINE; GLUTAMIC ACID; GLUTAMINE; LAMOTRIGINE; NEUROLEPTIC AGENT;

ANTERIOR CINGULATE; BOLD SIGNAL; CLINICAL TRIAL (TOPIC); COGNITION; COGNITIVE DEFECT; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUTAMATE DYSFUNCTION; HIGH RISK POPULATION; HUMAN; NEGATIVE SYNDROME; NEUROPSYCHOLOGICAL TEST; NEUROTRANSMISSION; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PROTON NUCLEAR MAGNETIC RESONANCE; PSYCHOSIS; SCHIZOPHRENIA; SHORT SURVEY; SIGNAL TRANSDUCTION; SYMPTOM;

EID: 84889657770     PISSN: None     EISSN: 16640640     Source Type: Journal    
DOI: 10.3389/fpsyt.2013.00151     Document Type: Short Survey

References (67)

1. Egerton A, Stone JM. The glutamate hypothesis of schizophrenia: neuroimaging and drug development. Curr Pharm Biotechnol (2012) 13(8):1500-12. doi: 10.2174/138920112800784961
2. Ventura J, Hellemann GS, Thames AD, Koellner V, Nuechterlein KH. Symptoms as mediators of the relationship between neurocognition and functional outcome in schizophrenia: a meta-analysis. Schizophr Res (2009) 113(2-3):189-99. doi:10.1016/j.schres.2009.03.035
3. Javitt DC. Treatment of negative and cognitive symptoms. Curr Psychiatry Rep (1999) 1(1):25-30. doi:10.1007/s11920-999-0007-z
4. Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans-psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry (1994) 51(3):199-214. doi:10.1001/archpsyc.1994.03950030035004
5. Newcomer JW, Farber NB, Jevtovic-Todorovic V, Selke G, Melson AK, Hershey T, et al. Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. Neuropsychopharmacology (1999) 20(2):106-18. doi:10.1016/s0893-133x(98)00067-0
6. Malhotra AK, Pinals DA, Weingartner H, Sirocco K, Missar CD, Pickar D, et al. NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers. Neuropsychopharmacology (1996) 14(5):301-7. doi:10.1016/0893-133x(95)00137-3
7. Malhotra AK, Pinals DA, Adler CM, Elman I, Clifton A, Pickar D, et al. Ketamine-induced exacerbation of psychotic symptoms and cognitive impairment in neuroleptic-free schizophrenics. Neuropsychopharmacology (1997) 17(3):141-50. doi:10.1016/S0893-133X(97)00036-5
8. Lahti AC, Koffel B, Laporte D, Tamminga CA. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology (1995) 13(1):9-19. doi:10.1016/0893-133X(94)00131-I
9. Krystal JH, Perry EB, Gueorguieva R, Belger A, Madonich SH, Abi-Dargham A, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine-implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry (2005) 62(9):985-95. doi:10.1001/archpsyc.62.9.985
10. Holcomb HH, Lahti AC, Medoff DR, Cullen T, Tamminga CA. Effects of noncompetitive NMDA receptor blockade on anterior cingulate cerebral blood flow in volunteers with schizophrenia. Neuropsychopharmacology (2005) 30(12):2275-82. doi:10.1038/sj.npp.1300824
11. Deakin JFW, Lees J, McKie S, Hallak JEC, Williams SR, Dursun SM. Glutamate and the neural basis of the subjective effects of ketamine. Arch Gen Psychiatry (2008) 65(2):154-64. doi:10.1001/archgenpsychiatry.2007.37
12. De Simoni S, Schwarz AJ, O'Daly OG, Marquand AF, Brittain C, Gonzales C, et al. Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers. Neuroimage (2013) 64:75-90. doi:10.1016/j.neuroimage.2012.09.037
13. Holcomb HH, Lahti AC, Medoff DR, Weiler M, Tamminga CA. Sequential regional cerebral blood flow brain scans using PET with (H2O)-O-15 demonstrate ketamine actions in CNS dynamically. Neuropsychopharmacology (2001) 25(2):165-72. doi:10.1016/s0893-133x(01)00229-9
14. Pilowsky LS, Bressan RA, Stone JM, Erlandsson K, Mulligan RS, Krystal JH, et al. First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients. Mol Psychiatry (2006) 11(2):118-9. doi:10.1038/sj.mp.4001751
15. Stone JM, Erlandsson K, Arstad E, Squassante L, Teneggi V, Bressan RA, et al. Relationship between ketamine-induced psychotic symptoms and NMDA receptor occupancy-a I-123 CNS-1261 SPET study. Psychopharmacology (2008) 197(3):401-8. doi:10.1007/s00213-007-1047-x
16. Snyder J, Wilman A. Field strength dependence of PRESS timings for simultaneous detection of glutamate and glutamine from 1.5 to 7 T. J Magn Reson (2010) 203(1):66-72. doi:10.1016/j.jmr.2009.12.002
17. Rothman DL, De Feyter HM, de Graaf RA, Mason GF, Behar KL. C-13 MRS studies of neuroenergetics and neurotransmitter cycling in humans. NMR Biomed (2011) 24(8):943-57. doi:10.1002/nbm.1772
18. Bustillo JR, Rowland LM, Mullins P, Jung R, Chen H, Qualls C, et al. H-1-MRS at 4 Tesla in minimally treated early schizophrenia. Mol Psychiatry (2010) 15(6):629-36. doi:10.1038/mp.2009.121
19. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J, et al. Glutamate and glutamine measured with 4.0 T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry (2002) 159(11):1944-6. doi:10.1176/appi.ajp.159.11.1944
20. Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci (1997) 17(8):2921-7.
21. Iltis I, Koski DM, Eberly LE, Nelson CD, Deelchand DK, Valette J, et al. Neurochemical changes in the rat prefrontal cortex following acute phencyclidine treatment: an in vivo localized H-1 MRS study. NMR Biomed (2009) 22(7):737-44. doi:10.1002/nbm.1385
22. Kim SY, Lee H, Kim HJ, Bang E, Lee SH, Lee DW, et al. In vivo and ex vivo evidence for ketamine-induced hyperglutamatergic activity in the cerebral cortex of the rat: potential relevance to schizophrenia. NMR Biomed (2011) 24(10):1235-42. doi:10.1002/nbm.1681
23. Rowland LM, Bustillo JR, Mullins PG, Jung RE, Lenroot R, Landgraf E, et al. Effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4-T proton MRS study. Am J Psychiatry (2005) 162(2):394-6. doi:10.1176/appi.ajp.162.2.394
24. Stone JM, Dietrich C, Edden R, Mehta MA, De Simoni S, Reed LJ, et al. Ketamine effects on brain GABA and glutamate levels with 1H-MRS: relationship to ketamine-induced psychopathology. Mol Psychiatry (2012) 17(7):664-5. doi:10.1038/mp.2011.171
25. Homayoun H, Moghaddam B. NMDA receptor hypofunction produces opposite effects on prefrontal cortex Interneurons and pyramidal neurons. J Neurosci (2007) 27(43):11496-500. doi:10.1523/jneurosci.2213-07.2007
26. Reid MA, Stoeckel LE, White DM, Avsar KB, Bolding MS, Akella NS, et al. Assessments of function and biochemistry of the anterior cingulate cortex in schizophrenia. Biol Psychiatry (2010) 68(7):625-33. doi:10.1016/j.biopsych.2010.04.013
27. Shirayama Y, Obata T, Matsuzawa D, Nonaka H, Kanazawa Y, Yoshitome E, et al. Specific metabolites in the medial prefrontal cortex are associated with the neurocognitive deficits in schizophrenia: a preliminary study. Neuroimage (2010) 49(3):2783-90. doi:10.1016/j.neuroimage.2009.10.031
28. Tayoshi S, Sumitani S, Taniguchi K, Shibuya-Tayoshi S, Numata S, Iga J, et al. Metabolite changes and gender differences in schizophrenia using 3-Tesla proton magnetic resonance spectroscopy (H-1-MRS). Schizophr Res (2009) 108(1-3):69-77. doi:10.1016/j.schres.2008.11.014
29. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RWJ, Rajakumar N, et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry (2003) 160(12):2231-3. doi:10.1176/appi.ajp.160.12.2231
30. Wood SJ, Yucel M, Wellard RM, Harrison BJ, Clarke K, Fornito A, et al. Evidence for neuronal dysfunction in the anterior cingulate of patients with schizophrenia: a proton magnetic resonance spectroscopy study at 3 T. Schizophr Res (2007) 94(1-3):328-31. doi:10.1016/j.schres.2007.05.008
31. Kegeles LS, Mao XL, Stanford AD, Girgis R, Ojeil N, Xu XY, et al. Elevated prefrontal cortex gamma-aminobutyric acid and glutamate-glutamine levels in schizophrenia measured in vivo with proton magnetic resonance spectroscopy. Arch Gen Psychiatry (2012) 69(5):449-59. doi:10.1001/archgenpsychiatry.2011.1519
32. Choe BY, Kim KT, Suh TS, Lee C, Paik IH, Bahk YW, et al. 1H magnetic resonance spectroscopy characterization of neuronal dysfunction in drug-naive, chronic schizophrenia. Acad Radiol (1994) 1(3):211-6. doi:10.1016/s1076-6332(05)80716-0
33. Theberge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malla AK, et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry (2007) 191:325-34. doi:10.1192/bjp.bp.106.033670
34. Aoyama N, Theberge J, Drost DJ, Manchanda R, Northcott S, Neufeld RWJ, et al. Grey matter and social functioning correlates of glutamatergic metabolite loss in schizophrenia. Br J Psychiatry (2011) 198(6):448-56. doi:10.1192/bjp.bp.110.079608
35. Luykx JJ, Laban KG, van den Heuvel MP, Boks MPM, Mandl RCW, Kahn RS, et al. Region and state specific glutamate downregulation in major depressive disorder: a meta-analysis of H-1-MRS findings. Neurosci Biobehav Rev (2012) 36(1):198-205. doi:10.1016/j.neubiorev.2011.05.014
36. Yoo SY, Yeon S, Choi CH, Kang DH, Lee JM, Shin NY, et al. Proton magnetic resonance spectroscopy in subjects with high genetic risk of schizophrenia: investigation of anterior cingulate, dorsolateral prefrontal cortex and thalamus. Schizophr Res (2009) 111(1-3):86-93. doi:10.1016/j.schres.2009.03.036
37. de la Fuente-Sandoval C, Leon-Ortiz P, Favila R, Stephano S, Mamo D, Ramirez-Bermudez J, et al. Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. Neuropsychopharmacology (2011) 36(9):1781-91. doi:10.1038/npp.2011.65
38. Egerton A, Brugger S, Raffin M, Barker GJ, Lythgoe DJ, McGuire PK, et al. Anterior cingulate glutamate levels related to clinical status following treatment in first-episode schizophrenia. Neuropsychopharmacology (2012) 37(11):2515-21. doi:10.1038/npp.2012.113
39. Stanley JA, Williamson PC, Drost DJ, Rylett RJ, Carr TJ, Malla A, et al. An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. Schizophr Bull (1996) 22(4):597-609. doi:10.1093/schbul/22.4.597
40. Bartha R, Williamson PC, Drost DJ, Malla A, Carr TJ, Cortese L, et al. Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. Arch Gen Psychiatry (1997) 54(10):959-65. doi:10.1001/archpsyc.1997.01830220085012
41. Ohrmann P, Siegmund A, Suslow T, Spitzberg K, Kersting A, Arolt V, et al. Evidence for glutamatergic neuronal dysfunction in the prefrontal cortex in chronic but not in first-episode patients with schizophrenia: a proton magnetic resonance spectroscopy study. Schizophr Res (2005) 73(2-3):153-7. doi:10.1016/j.schres.2004.08.021
42. Ohrmann P, Kugel H, Bauer J, Siegmund A, Kolkebeck K, Suslow T, et al. Learning potential on the WCST in schizophrenia is related to the neuronal integrity of the anterior cingulate cortex as measured by proton magnetic resonance spectroscopy. Schizophr Res (2008) 106(2-3):156-63. doi:10.1016/j.schres.2008.08.005
43. Bustillo JR, Chen HJ, Gasparovic C, Mullins P, Caprihan A, Qualls C, et al. Glutamate as a marker of cognitive function in schizophrenia: a proton spectroscopic imaging study at 4 Tesla. Biol Psychiatry (2011) 69(1):19-27. doi:10.1016/j.biopsych.2010.08.024
44. Rowland LM, Spieker EA, Francis A, Barker PB, Carpenter WT, Buchanan RW. White matter alterations in deficit schizophrenia. Neuropsychopharmacology (2009) 34(6):1514-22. doi:10.1038/npp.2008.207
45. Reid MA, Kraguljac NV, Avsar KB, White DM, den Hollander JA, Lahti AC. Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia. Schizophr Res (2013) 147(2-3):348-54. doi:10.1016/j.schres.2013.04.036
46. Rowland L, Kontson K, West J, Edden R, Zhu H, Wijtenburg S, et al. In vivo measurements of glutamate, GABA, and NAAG in schizophrenia. Schizophr Bull (2012) 39(5):1096-104. doi:10.1093/schbul/sbs092
47. de la Fuente-Sandoval C, León-Ortiz P, Azcárraga M, Stephano S, Favila R, Díaz-Galvis L, et al. Glutamate levels in the associative striatum before and after 4 weeks of antipsychotic treatment in first-episode psychosis: a longitudinal proton magnetic resonance spectroscopy study. JAMA Psychiatry (2013) 70(10):1057-66. doi:10.1001/jamapsychiatry.2013.289
48. Ota M, Ishikawa M, Sato N, Hori H, Sasayama D, Hattori K, et al. Glutamatergic changes in the cerebral white matter associated with schizophrenic exacerbation. Acta Psychiatr Scand (2012) 126(1):72-8. doi:10.1111/j.1600-0447.2012.01853.x
49. Demjaha A, Egerton A, Murray R, Kapur S, Howes O, Stone J, et al. Antipsychotic treatment resistance in schizophrenia associated with elevated glutamate levels but normal dopamine function. Biol Psychiatry (2013). [Epub ahead of print]. doi:10.1016/j.biopsych.2013.06.011
50. Ongur D, Jensen JE, Prescot AP, Stork C, Lundy M, Cohen BM, et al. Abnormal glutamatergic neurotransmission and neuronal-glial interactions in acute mania. Biol Psychiatry (2008) 64(8):718-26. doi:10.1016/j.biopsych.2008.05.014
51. Lyne JP, Kinsella A, O'Donoghue B. Can we combine symptom scales for collaborative research projects? J Psychiatr Res (2012) 46(2):233-8. doi:10.1016/j.jpsychires.2011.10.002
52. Wilmsmeier A, Ohrmann P, Suslow T, Siegmund A, Koelkebeck K, Rothermundt M, et al. Neural correlates of set-shifting: decomposing executive functions in schizophrenia. J Psychiatry Neurosci (2010) 35(5):321-9. doi:10.1503/jpn.090181
53. Rusch N, van Elst LT, Valerius G, Buechert M, Thiel T, Ebert D, et al. Neurochemical and structural correlates of executive dysfunction in schizophrenia. Schizophr Res (2008) 99(1-3):155-63. doi:10.1016/j.schres.2007.05.024
54. Tandon N, Bolo NR, Sanghavi K, Mathew IT, Francis AN, Stanley JA, et al. Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy. Schizophr Res (2013) 148(1-3):59-66. doi:10.1016/j.schres.2013.05.024
55. Ohrmann P, Siegmund A, Suslow T, Pedersen A, Spitzberg K, Kersting A, et al. Cognitive impairment and in vivo metabolites in first-episode neuroleptic-naive and chronic medicated schizophrenic patients: a proton magnetic resonance spectroscopy study. J Psychiatr Res (2007) 41(8):625-34. doi:10.1016/j.jpsychires.2006.07.002
56. Fusar-Poli P, Stone JM, Broome MR, Valli I, Mechelli A, McLean MA, et al. Thalamic glutamate levels as a predictor of cortical response during executive functioning in subjects at high risk for psychosis. Arch Gen Psychiatry (2011) 68(9):881-90. doi:10.1001/archgenpsychiatry.2011.46
57. Valli I, Stone J, Mechelli A, Bhattacharyya S, Raffin M, Allen P, et al. Altered medial temporal activation related to local glutamate levels in subjects with prodromal signs of psychosis. Biol Psychiatry (2011) 69(1):97-9. doi:10.1016/j.biopsych.2010.08.033
58. Hutcheson NL, Reid MA, White DM, Kraguljac NV, Avsar KB, Bolding MS, et al. Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging. Schizophr Res (2012) 140(1-3):136-42. doi:10.1016/j.schres.2012.06.039
59. Tibbo P, Hanstock C, Valiakalayil A, Allen P. 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry (2004) 161(6):1116-8. doi:10.1176/appi.ajp.161.6.1116
60. Tebartz van Elst L, Valerius G, Buchert M, Thiel T, Rusch N, Bubl E, et al. Increased prefrontal and hippocampal glutamate concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry (2005) 58(9):724-30. doi:10.1016/j.biopsych.2005.04.041
61. Stone JM, Howes OD, Egerton A, Kambeitz J, Allen P, Lythgoe DJ, et al. Altered relationship between hippocampal glutamate levels and striatal dopamine function in subjects at ultra high risk of psychosis. Biol Psychiatry (2010) 68(7):599-602. doi:10.1016/j.biopsych.2010.05.034
62. Szulc A, Konarzewskaa B, Galinska-Skoka B, Lazarczyka J, Waszkiewicza N, Tarasowb E, et al. Proton magnetic resonance spectroscopy measures related to short-term symptomatic outcome in chronic schizophrenia. Neurosci Lett (2013) 547:37-41. doi:10.1016/j.neulet.2013.04.051
63. Tiihonen J, Wahlbeck K. Glutamatergic drugs for schizophrenia. Cochrane Database Syst Rev (2006). doi:10.1002/14651858.CD003730.pub2
64. Singh SP, Singh V. Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia. CNS Drugs (2011) 25(10):859-85. doi:10.2165/11586650-000000000-00000
65. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine-support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry (2000) 57(3):270-6. doi:10.1001/archpsyc.57.3.270
66. Chatterton JE, Awobuluyi M, Premkumar LS, Takahashi H, Talantova M, Shin Y, et al. Excitatory glycine receptors containing the NR3 family of NMDA receptor subunits. Nature (2002) 415(6873):793-8. doi:10.1038/nature715
67. Olbrich HM, Valerius G, Rüsch N, Buchert M, Thiel T, Hennig J, et al. Frontolimbic glutamate alterations in first episode schizophrenia: evidence from a magnetic resonance spectroscopy study. World J Biol Psychiatry (2008) 9(1):59-63. doi:10.1080/15622970701227811